CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026SENS-501 Audiogene trial ongoing; six-month efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results